Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.90B

Market cap82.90B

Price-Earnings ratio

19.90

Price-Earnings ratio19.90

Dividend yield

0.46%

Dividend yield0.46%

Average volume

665.39K

Average volume665.39K

High today

—

High today—

Low today

—

Low today—

Open price

$819.09

Open price$819.09

Volume

0.00

Volume0.00

52 Week high

$859.34

52 Week high$859.34

52 Week low

$575.93

52 Week low$575.93

Stock Snapshot

The current Regeneron(REGN) stock price is $804.00, with a market capitalization of 82.9B. The stock trades at a price-to-earnings (P/E) ratio of 19.90 and offers a dividend yield of 0.46%.

On 2026-10-26, Regeneron(REGN) shares started trading at $819.09, with intraday highs of — and lows of —.

Trading volume for Regeneron(REGN) stock has reached 0, versus its average volume of 665.39K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $575.93.

REGN News

Reuters 53m

Regeneron extends US agreement for additional supply of Ebola treatment - Reuters

...

Simply Wall St 1h

Regeneron Pharmaceuticals Could Be 5% Undervalued Following Fresh Libtayo Phase 3 Data

Regeneron Pharmaceuticals (REGN) is back in focus after late-breaking C POST Phase 3 data at ESMO 2026 showed sustained disease-free survival and emerging overa...

Simply Wall St 3d

Regeneron Pharmaceuticals Pushes Ahead In Weight Loss With Two Distinct Drug Bets

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indic...

Analyst ratings

65%

of 31 ratings

Buy

64.5%

Hold

29%

Sell

6.5%

More REGN News

TipRanks 5d

Regeneron price target raised to $980 from $960 at TD Cowen

TD Cowen raised the firm’s price target on Regeneron (REGN) to $980 from $960 and keeps a Buy rating on the shares. The fim updated its model ahead of Q3 result...

The Motley Fool 7d

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

The weight-loss market is growing rapidly, and while long-term projections differ on how large it will become, they generally agree that it will maintain its up...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.